REZDIFFRA

Growth

resmetirom

Madrigal Pharmaceuticals

NDAORALTABLETPriority Review

Approved

Mar 2024

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Data completeness

6/8 — Strong

Priority Review

REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals is thyroid hormone receptor beta agonists [moa]. Approved for non-alcoholic fatty liver disease, metabolic dysfunction-associated steatohepatitis. First approved in 2024.

Drug data last refreshed Yesterday

See 10 jobs working on REZDIFFRA →

Mechanism of Action

Thyroid Hormone Receptor beta Agonists

Pharmacologic Class:

Thyroid Hormone Receptor beta Agonist

Indications (2)

Non-Alcoholic Fatty Liver Disease(2)Metabolic Dysfunction-Associated Steatohepatitis

Worked on REZDIFFRA at Madrigal Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (8)

NCT07541469N/ARecruiting

Rezdiffra Pregnancy and Lactation Registry

Started Mar 2026

10 enrolled

MASH - Metabolic Dysfunction-Associated Steatohepatitis

NCT07335601Phase 2Recruiting

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Started Dec 2025

120 enrolled

MASH - Metabolic Dysfunction-Associated Steatohepatitis

NCT07216313Phase 1Completed

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Started Sep 2025

40 enrolled

Healthy

NCT06397872Phase 1Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Started Mar 2024

28 enrolled

Renal Impairment

NCT05500222Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Started Aug 2022

700 enrolled

NASHCirrhosis, Liver

REZDIFFRA

Mechanism of Action

Indications (2)

Clinical Trials (8)

Why This Matters for Your Career